|Articles|February 1, 2000

Ace Inhibitors and Their Utilization in Managed Care
Volume 6
Issue 3 Suppl

Case 2: Hypertension Therapy in Managed Care (Quiz)

Download PDF: Case 2: Hypertension Therapy in Managed Care (Quiz)

Articles in this issue

over 26 years ago

Article

Participating Faculty

over 26 years ago

Article

Continuing Medical and Pharmacy Educational Objectives

over 26 years ago

Article

Glossary of Abbreviations

over 26 years ago

Article

Class Effects of Angiotensin-Converting Enzyme Inhibitors (Quiz)

over 26 years ago

Article

The Impact of Angiotensin-Converting Enzyme Inhibitors on Managed Care: Economic, Clinical, and Humanistic Outcomes (Quiz)

over 26 years ago

Article

Case 1: Hypertension; Impaired Glucose Tolerance (Quiz)

over 26 years ago

Article

Case 3: Coronary Heart Disease; Hypertension

over 26 years ago

Article

Case 4: Systolic Hypertension; Diabetes Mellitus; Renal Dysfunction; and the Use of ACE Inhibitors in African-American Population

over 26 years ago

Article

Case 5: Congestive Heart Failure; Prior Myocardial Infarction; Economic Consideration of Care in Medicare Population

over 26 years ago

Article

Case 6: Alcoholic Cardiomyopathy; Hypertension

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Orthopedic surgeon holds bone x-ray | Image Credit: © tippapatt - stock.adobe.com

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

ByHannah I. Travers, MD,Mikhail Kuznetsov, MD,John Mazzocco, MD,Nicholas Pagani, MD,Tricia Ide, DNP, RN,Brian L. Hollenbeck, MD,Eric L. Smith, MD

June 3rd 2026

Case 2: Hypertension Therapy in Managed Care (Quiz)

Articles in this issue

Related Content

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

Trending on AJMC

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

Social Factors Shape Diabetes, Dementia Risk Across Populations

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD